Granted Patent
B2
US 12,226,450 · App. 17/810,513 · Granted Feb 18, 2025
Peptides and methods for treating disease
Inventors:
David Hal Wagner, Jr. (Denver, CO); Martin Glenn Yussman (Denver, CO); Charles W. Henry (Denver, CO)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to β-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.
Claims (20)
1. A peptide of six amino acids in length comprising the amino acid sequence of SEQ ID NO: 50.
2. The peptide of claim 1 , wherein the peptide is formulated to be administered via intramuscular (IM) delivery, intravenous (IV) delivery, subcutaneous (SC) delivery, oral delivery, gavage delivery, emollient/skin delivery, transdermal patch, and/or intranasally.
3. The peptide of claim 1 , wherein the peptide is produced synthetically.
4. The peptide of claim 1 , wherein the N-terminal amino acid is acetylated.
5. A pharmaceutical composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising a peptide of claim 1 , a sterile solubilizing agent, and a buffering agent.
7. The pharmaceutical composition of claim 6 further comprising a sugar.
8. The pharmaceutical composition of claim 6 , wherein the solubilizing agent is water.
9. The pharmaceutical composition of claim 6 , wherein the peptide is pegylated, glycosylated, or comprises a chemical medication, or is acetylated at the N-terminus.
10. A method for modulating and/or reducing diabetes mellitus in a subject, the method comprising administering a peptide of claim 1 to the subject.
11. The method of claim 10 , wherein the subject is a dog, cat, or horse.
12. The method of claim 10 , wherein administering the peptide alters the cytokine expression profile of a cell population treated with said peptide.
13. The method of claim 10 , wherein said peptide binds to an antigen presenting cell.
14. The method of claim 13 , wherein the antigen presenting cell is a bone marrow derived cell type that expresses CD40 of approximately 45 kDa.
15. The method of claim 10 , wherein administering said peptide modulates and/or reduces IFN-γ in the subject.
16. The method of claim 10 , wherein administering said peptide modulates and/or reduces interleukin-2 signaling in the subject.
17. The method of claim 10 , wherein administering said peptide modulates and/or reduces expression of interleukin 17 (IL-17) by a cell in the subject.
18. The method of claim 10 , wherein administering said peptide modulates and/or reduces blood glucose levels of the subject.
19. The method of claim 10 , wherein administering said peptide modulates and/or reduces fructosamine serum values in the subject.
20. The method of claim 10 , wherein administering said peptide modifies, changes, or affects the c-peptide levels of the subject.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 5, 2025
From: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
To: OP-T LLC
Reel/Frame 071026/0175 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 4, 2024
From: YUSSMAN, MARTIN GLENN; HENRY, CHARLES W.
To: OP-T LLC
Reel/Frame 066637/0101 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 4, 2024
From: WAGNER, DAVID H., JR.
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 066637/0108 →
Continuity (3)
Provisional Application
62873776
· Jul 12, 2019
References Cited (173)
US 4642295A
· Baker
· 1987
[cited by applicant]
US 6264951B1
· Armitage
· 2001
[cited by applicant]
US 7087573B1
· Lazarus
· 2006
[cited by applicant]
US 7741280B2
· Guichard et al.
· 2010
[cited by applicant]
US 9562088B2
· Wagner
· 2017
[cited by applicant]
US 20030078269A1
· Pearson et al.
· 2003
[cited by applicant]
US 20050202531A1
· Toporik
· 2005
[cited by applicant]
US 20070041971A1
· Wagner
· 2007
[cited by applicant]
US 20150366946A1
· Vol et al.
· 2015
[cited by applicant]
US 20160200823A1
· Burkly et al.
· 2016
[cited by applicant]
US 20190194290A1
· Wagner, Jr. et al.
· 2019
[cited by applicant]
WO WO2008036675A2
· 2008
[cited by applicant]
WO WO2019032945A1
· 2019
[cited by applicant]
WO WO2019136307A1
· 2019
[cited by applicant]
WO WO2021011437A1
· 2021
[cited by applicant]
WO WO2021212013A2
· 2021
[cited by applicant]
WO WO2021231898A2
· 2021
[cited by applicant]
UniProtKB/Swiss-Prot: P51749.1, 2023, 2 pages (Year: 2023).
[cited by examiner]
Aart et al., Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation, Journal of Neuroinflammation, 14: 105-118 (2014).
[cited by applicant]
Advisory Action for U.S. Appl. No. 13/880,387, mailed May 27, 2016, 4 pages.
[cited by applicant]
Allen et al., “Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade,” The Journal of Peptide Research, 65(6): 591-604 (2005).
[cited by applicant]
Amer. Diabetes Association Diagnosis and Classification of Diabetes Mellitus, Diabetes Care, 2014, 37, Suppl.I :S8 I-S90.
[cited by applicant]
Armitage et al., “CD40L: a multi-functional ligand,” Semin Immunol, 5(6): 404-412 (1993).
[cited by applicant]
Aruffo et al., “The CD40 Ligand, gp39, Is Defective in Activated T Cells from Patients with X-Linked Hyper-IgM Syndrome,” Cell, 72: 291-300 (1993).
[cited by applicant]
Attwood, “The Babel of Bioinformatics,” Science, 290(5491): 471-473 (2000).
[cited by applicant]
Bai et al., “Cerebrospinal Fluid and Blood Cytokines as Biomarkers for Multiple Sclerosis: A Systematic Review and Meta-Analysis of 226 Studies With 13,526 Multiple Sclerosis Patients,”
[cited by applicant]
Bak et al., “Physicochemical and Formulation Developability Assessment for Therapeutic Peptide Delivery—A Primer,” The AAPS Journal, 17(1): 144-155 (2015).
[cited by applicant]
Balasa et al., “CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice,” J Immunol, 159(9): 4620-4627 (1997).
[cited by applicant]
Becker et al., “CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes,” J Cell Biol, 158(7): 1277-1285 (2002).
[cited by applicant]
Bee et al., “Exploring the Dynamic Range of the Kinetic Exclusion Assay in Characterizing Antigen-Antibody Interactions,” Plos One, 7(4): e36261 (2012).
[cited by applicant]
Biosyn., “Why acetylate and amidate a peptide,” accessed on Mar. 22, 2021 at <https://biosyn.com/faq/why-acetylate-and-amidate-apeptide.aspx>: 1 page (2008).
[cited by applicant]
Bojadzic et al., “CD40-targeting KGYY15 peptides do not efficiently block the CD40-CD40L interaction,” Diabetologia, 62: 2158-2160 (2019).
[cited by applicant]
Bourgeois et al., “A Role for CD40 Expression on CD8+ T cells in the Generation of CD8+ T Cell Memory,” Science, 297: 2060-2063 (2002).
[cited by applicant]
Buzzard et al., “Multiple Sclerosis: Basic and Clinical,” Adv. Neurobiol., 2017, 15: 211-252.
[cited by applicant]
Carter et al., “CD40 engagement of CD4+ CD40+ T cells in a neo-self antigen disease model ablates CTLA-4 expression and indirectly impacts tolerance,” Eur J Immunol, 42: 424-435 (2012).
[cited by applicant]
Catchpole et al., “Canine diabetes mellitus: can old dogs teach us new tricks?,” Diabetologia, 48: 1948-1956 (2005).
[cited by applicant]
Ceccarelli et al., “Microglia extracellular vesicles: focus on molecular composition and biological function,”
[cited by applicant]
Chatzigeorgiou et al., “Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance,” PNAS, 111(7): 2686-2691 (2014).
[cited by applicant]
Chen et al., “CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system,”
[cited by applicant]
Cipollone et al., “Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control,” Diabetologia, 48: 1…
[cited by applicant]
Cooper et al., “Cutting Edge: TCR Revision Occurs in Germinal Centers,” J Immunol, 73: 6532-6536 (2004).
[cited by applicant]
Davidson et al., “Co-Stimulatory Blockade in the Treatment of Murine Systemic Lupus Erthematosus (SLE),” NY Acad Sci. 987: 188-198 (2003).
[cited by applicant]
De Ramon et al., “CD154-CD40 T-cell co-stimulation pathway is a key mechanism in kidney ischemia-reperfusion injury,” Kidney International, 88(3): 538-549 (2015).
[cited by applicant]
Deambrosis et al., “Inhibition of CD40-CD154 costimulatory pathway by a cyclic peptide targeting CD154,” J. Mol. Med., 87: 181-197 (2009).
[cited by applicant]
DeGraba et al., “Efficacy of an Interdisciplinary Intensive Outpatient Program in Treating Combat-Related Traumatic Brain Injury and Psychological Health Conditions,”
[cited by applicant]
Devaraj et al., “Increased Monocytic Activity and Biomarkers of Inflammation in Patients With Type 1 Diabetes,” Diabetes, 55: 774-779 (2006).
[cited by applicant]
Druzd et al., “Lymphocyte Circadian Clocks Control Lymph Node Trafficking and Adaptive Immune Responses,” Immunity, 2017; 46: 120-32 [PubMed: 28087238].
[cited by applicant]
Durie, F.H., R.A. Fava, T.M. Foy, A. Aruffo, J.A. Ledbetter, and R.J. Noelle. 1993.
[cited by applicant]
Edwards et al., “Interleukin-6 is associated with acute concussion in military combat personnel,”
[cited by applicant]
Elliott et al., “Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis,”
[cited by applicant]
Ellmark et al., “Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library,” Immunology, 106: 456-463 (2002).
[cited by applicant]
Eshaghi et al., “Progression of regional grey matter atrophy in multiple sclerosis,”
[cited by applicant]
Fan et al., “The emerging role of exosome-derived non-coding RNAs in cancer biology,”
[cited by applicant]
Fanslow et al., “Recombinant CD40 ligand exerts potent biologic effects on T cells,” J Immunol, 152(9): 4262-4269 (1994).
[cited by applicant]
Final Action for U.S. Appl. No. 13/880,387, mailed Feb. 18, 2016, 8 pages.
[cited by applicant]
Goetzl et al., “Altered levels of plasma neuron-derived exosomes and their cargo proteins characterize acute and chronic mild traumatic brain injury,”
[cited by applicant]
Goetzl et al., “Traumatic brain injury increases plasma astrocyte-derived exosome levels of neurotoxic complement proteins,”
[cited by applicant]
Goodnow et al., “Pathways for self-tolerance and the treatment of autoimmune diseases,” Lancet, 357: 2115-2121 (2001).
[cited by applicant]
Gottlieb et al., “Managing feline diabetes: current perspectives,” Vet Med (Auckl), 9: 33-42 (2018).
[cited by applicant]
Grabstein et al., “The regulation of T cell-dependent antibody formation in vitro by CD40 ligand and IL-2,” J Immunol, 150(8): 3141-3147 (1993).
[cited by applicant]
Grossman, M.E., E. Davila, and E. Celis. 2001.
[cited by applicant]
Guo et al., “CD40L-Dependent Pathway Is Active at Various Stages of Rheumatoid Arthritis Disease Progression,” J Immunol, 198(11): 4490-4501 (2017).
[cited by applicant]
Guptill, L., et al., Vet. J., 2003, 165:240-47.
[cited by applicant]
Hamlett et al., “Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome,”
[cited by applicant]
Hancock., “Preventing and managing diabetes: an exemplar for NCDS,” C3 Collaborating for Health: pp. 1-8 (2012).
[cited by applicant]
Hart et al., “Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis,”
[cited by applicant]
Hartung et al., “Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017—continuity and change,”
[cited by applicant]
Heath et al., “Monoclonal antibodies to murine CD40 define two distinct functional epitopes,” Eur. J. Immunol., 24: 1828-1834 (1994).
[cited by applicant]
Hernandez et al., “CD40-CD40 Ligand Interaction between Dendritic Cells and CD8+ T Cells Is Needed to Stimulate Maximal T Cell Responses in the Absence of CD4+ T Cell Help,” J Immunol, 178(5) 2844-2852 (2007).
[cited by applicant]
Homann et al., “CD40L Blockade Prevents Autoimmune Diabetes by Induction of Bitypic NK/DC Regulatory Cells,” Immunity, 16: 403-415 (2002).
[cited by applicant]
Howard, L.M., and S.D. Miller. 2004.
[cited by applicant]
Huang et al., Resolving the Conundrum of Islet Transplantation by Linking Metabolic Dysregulation, Inflammation, and Immune Regulation, Endocrine Reviews, 29(5): 603-630 (2008).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US11/56860 dated Apr. 23, 2013.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US11/56860 mailed May 4, 2012.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/041744 mailed Nov. 13, 2020.
[cited by applicant]
Johnson et al., “Diabetes, Insulin Resistance, and Metabolic Syndrome in Horses,” J Diabetes Sci Technol, 6(3): 534-540 (2012).
[cited by applicant]
Kalatha et al., “Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort,”
[cited by applicant]
Karpusas et al., “2 å crystal structure of an extracellular fragment of human CD40 ligand,” Structure, 3(10): 1031-1039 (1995).
[cited by applicant]
Khan et al., “Differential peptide binding to CD40 evokes counteractive responses,” Hum Immunol, 73(5): 465-469 (2012).
[cited by applicant]
Kitagawa, M., et al.—2014—Modern Rheumatology. vol. 15-6, 423-426.
[cited by applicant]
Kobata et al., “Role of costimulatory molecules in autoimmunity,” Rev Immunogenet, 2(1): 74-80 (2000).
[cited by applicant]
Kutzelnigg et al., “Cortical demyelination and diffuse white matter injury in multiple sclerosis,”
[cited by applicant]
Laemmli ., “Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4,” Nature, 227: 680-685 (1970).
[cited by applicant]
Lederman et al., “Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help),” J. Exp. Med., 75(4): 1091-1101 (1992).
[cited by applicant]
Lederman et al., “Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help,” J Immunol, 149(1…
[cited by applicant]
Ledreux et al., “Assessment of Long-Term Effects of Sports-Related Concussions: Biological Mechanisms and Exosomal Biomarkers,”
[cited by applicant]
Ledreux et al., “Small Neuron-Derived Extracellular Vesicles from Individuals with Down Syndrome Propagate Tau Pathology in the Wildtype Mouse Brain,”
[cited by applicant]
Leighton et al., “A Practical Review of C-Peptide Testing in Diabetes,” Diabetes Ther, 8(3): 475-487 (2017).
[cited by applicant]
Liu et al., “NG2 glia are required for maintaining microglia homeostatic state,”
[cited by applicant]
Liu et al., “Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse,”
[cited by applicant]
Macaron et al., “Diagnosis and Management of Progressive Multiple Sclerosis,”
[cited by applicant]
Maggi et al., “Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis,”
[cited by applicant]
Marsh, Steven G.E. 2012. Human Immunology. vol. 73, 593-596.
[cited by applicant]
Matthews et al., “Utility of murine models for the study of spontaneous autoimmune type 1 diabetes,” Pediatric Diabetes, 6: 165-177 (2005).
[cited by applicant]
McWhirter, Sarah, et al.—1999—Biochemistry—vol. 96, 8408-8413.
[cited by applicant]
Munroe et al., “Proinflammatory Adaptive Cytokine and Shed Tumor Necrosis Factor Receptor Levels Are Elevated Preceding Systemic Lupus Erythematosus Disease Flare,” Arthritis Rheumatol, 66(7): 1888-1899 (2014).
[cited by applicant]
Najafian et al., “T cell costimulatory pathways: blockade for autoimmunity,”
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 13/880,387, mailed Sep. 21, 2016.
[cited by applicant]
Nourelden et al., “Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-Analysis,” Endocr. Metab. Immune Disord Drug Targets, 10: Abstract Only (2020).
[cited by applicant]
O'Kell et al., “Comparative Pathogenesis of Autoimmune Diabetes in Humans, NOD Mice, and Canines: Has a Valuable Animal Model of Type 1 Diabetes Been Overlooked?,” Diabetes, 66(7): 1443-1452 (2017).
[cited by applicant]
Official Action for European Application No. 11835055.2, date Feb. 9, 2017, 4 pages.
[cited by applicant]
Official Action for European Application No. 11835055.2, dated Jun. 14, 2016, 4 pages.
[cited by applicant]
Official Action for European Application No. 11835055.2, dated Nov. 20, 2014, 5 pages.
[cited by applicant]
Official Action for U.S. Appl. No. 13/880,387, mailed Jun. 24, 2015, 14 pages.
[cited by applicant]
Ontaneda., “Progressive Multiple Sclerosis,”
[cited by applicant]
Patel et al., “Recent developments in protein and peptide parenteral delivery approaches,” Ther. Deliv., 5(3): 337-365 (2014).
[cited by applicant]
Peng et al., “Microglia-Derived Exosomes Improve Spinal Cord Functional Recovery after Injury via Inhibiting Oxidative Stress and Promoting the Survival and Function of Endothelia Cells,”
[cited by applicant]
Pullen et al., “CD40 Signaling through Tumor Necrosis Factor Receptor-associated Factors (TRAFs): Binding Site Specificity and Activation of Downstream Pathways by Distinct TRAFs,” J Biol Chem, 274(20): 14246-14254 (199…
[cited by applicant]
Pulliam et al., “Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease,”
[cited by applicant]
Quezada et al., “Distinct Mechanisms of Action of Anti-CD154 in Early Versus Late Treatment of Murine Lupus Nephritis,” Arthritis & Rheumatism, 48(9): 2541-2554 (2003).
[cited by applicant]
Ramsdell et al., “CD40 ligand acts as a costimulatory signal for neonatal thymic gamma delta T cells,” J Immunol, 152(5): 2190-2197 (1994).
[cited by applicant]
Resetkova et al., “Antibody to gp39, the Ligand for CD40 Significantly Inhibits the Humoral Response from Graves' Thyroid Tissues Xenografted into Severe Combined Immunodeficient (SCID) Mice,” Thyroid, 6(4): 267-273 (19…
[cited by applicant]
Richards et al., “A peptide containing a novel FPGN CD40-binding sequence enhances adenoviral infection of murine and human dendritic cells,” Eur. J. Biochem., 270: 2287-2294 (2003).
[cited by applicant]
Rolink et al., “The SCID but Not the RAG-2 Gene Product Is Required for S ?- S? Heavy Chain Class Switching,” Immunity, 5(4): 319-330 (1996).
[cited by applicant]
Rosetti et al., “The many faces of Mac-1 in autoimmune disease,” Immunological Reviews, 269: 175-193 (2016).
[cited by applicant]
Ruiz et al., “Resolution of inflammation during multiple sclerosis,”
[cited by applicant]
Russo et al., “Platelet-Activating Factor Mediates CD40-Dependent Angiogenesis and Endothelial-Smooth Muscle Cell Interaction,” J Immunol, 171: 5489-5497 (2003).
[cited by applicant]
Santilli et al., “CD40/CD40L system and vascular disease,”
[cited by applicant]
Sarawar et al., “Stimulation via CD40 can substitute for CD4 T cell function in preventing reactivation of a latent herpesvirus,” PNAS, 98(11): 6325-6329 (2001).
[cited by applicant]
Schuh et al., “Features of Human CD3+CD20+ T Cells,” J. Immunol., 2016, 197(4): 1111-1117.
[cited by applicant]
Schönbeck et al., “CD154 (CD40 ligand),” The International Journal of Biochemistry and Cell Biology, 32(7): 687-693 (2000).
[cited by applicant]
Schönbeck et al., “The CD40/CD154 receptor/ligand dyad,” Cell Mol Life Sci, 58: 4-43 (2001).
[cited by applicant]
Seko et al., “Expression of tumour necrosis factor (TNF) receptor/ligand superfamily co-stimulatory molecules CD40, CD30L, CD27L, and OX40L in murine hearts with chronic ongoing myocarditis caused by Coxsackie virus B3,…
[cited by applicant]
Sharma et al., “Glioma-derived exosomes drive the differentiation of neural stem cells to astrocytes,”
[cited by applicant]
Shukshith et al., “Water for Pharmaceutical Use,” Int. J. Pharm. Sci. Rev. Res., 36(1): 199-204 (2016).
[cited by applicant]
Siracusa et al., “Astrocytes: Role and Functions in Brain Pathologies,”
[cited by applicant]
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends in Biotech, 18: 34-39 (2000).
[cited by applicant]
Stumpf et al., “Enhanced levels of CD154 (CD40 ligand) on platelets in patients with; chronic heart failure,” Eur J Heart Fail, 5: 629-637 (2003).
[cited by applicant]
Stys et al., “Recent advances in understanding multiple sclerosis,”
[cited by applicant]
Sun et al., “Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations,”
[cited by applicant]
Sun, Yonglian et al., “Co-stimulation agonists as a new immunotherapy for autoimmune diseases,” Trends Mol Med, 9(11): 483-489 (2003).
[cited by applicant]
Takada et al., “Integrin Binding to the Trimeric Interface of CD40L Plays a Critical Role in CD40/CD40L Signaling,” J. Immunol., 203: 1383-1391 (2019).
[cited by applicant]
Takahashi et al., “The role of extracellular vesicle microRNAs in cancer biology,”
[cited by applicant]
Takeda et al., “Neuronal Differentiation of Human Mesenchymal Stem Cells Using Exosomes Derived from Differentiating Neuronal Cells,”
[cited by applicant]
Thouvenot., “Update on clinically isolated syndrome,”
[cited by applicant]
Toubi et al., “The Role of CD40-CD154 Interactions in Autoimmunity and the Benefit of Disrupting this Pathway,” Autoimmunity, 37: 457-464 (2004).
[cited by applicant]
Townsend et al., “CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid ?-peptide,” Eur J Immunol, 35: 901-910 (2005).
[cited by applicant]
Vaitaitis et al., “A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis,”
[cited by applicant]
Vaitaitis et al., “A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice,” Diabetologia, 57: 2366-2373 (2014).
[cited by applicant]
Vaitaitis et al., “Biomarker discovery in pre-Type 1 Diabetes; Th40 cells as a predictive risk factor,”
[cited by applicant]
Vaitaitis et al., “CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor Reply to Pagni PP, Wolf A, Lo Conte M et al.[letter],” Diabetologia, 62: 1730-1731 (2…
[cited by applicant]
Vaitaitis et al., “Cutting Edge: CD40-Induced Expression of Recombination Activating Gene (RAG) 1 and RAG2: A Mechanism for the Generation of Autoaggressive T Cells in the Periphery,” J Immunol 170: 3455-3459 (2003).
[cited by applicant]
Vaitaitis et al., “High Distribution of CD40 and TRAF2 in Th40 T Cell Rafts Leads to Preferential Survival of this Auto-Aggressive Population in Autoimmunity,” PlosOne, 3(4): e2076 (11 pages) (2008).
[cited by applicant]
Vaitaitis et al., “Th40 cells (CD4+CD40+ Tcells) drive a more severe form of Experimental Autoimmune Encephalomyelitis than conventional CD4 T cells,” Plos One 12(2): e0172037 (24 pages) (2017).
[cited by applicant]
Vaitaitis et al., Molecular Immunology. vol. 47, 2307-2313 (2010).
[cited by applicant]
Vaitaitis et al., “An Alternative Role for Foxp3 As an Effector T Cell Regulator Controlled through CD40,” J Immunol, 191(2): 717-725 (2013).
[cited by applicant]
Vaitaitis, G.M et al.—2012—PlosOne—vol. 7, e38708, p. 1-13.
[cited by applicant]
Van Kooten et al., “CD40-CD40 ligand,”
[cited by applicant]
Varo et al., “Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients,” Circulation, 107: 2664-2669 (2003).
[cited by applicant]
Vaz et al., “Phenotypic Effects of Wild-Type and Mutant SOD1 Expression in N9 Murine Microglia at Steady State, Inflammatory and Immunomodulatory Conditions,”
[cited by applicant]
Verma et al., “Not Just an Adhesion Molecule: LFA-1 Contact Tunes the T Lymphocyte Program,” The Journal of Immunology, 199: 1213-1221 (2017).
[cited by applicant]
Wagner et al., “Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes,” PNAS, 99(6): 3782-3787 (2002).
[cited by applicant]
Wagner et al., “Increased expression of CD40 on thymocytes and peripheral T cells in autoimmunity: a mechanism for acquiring changes in the peripheral T cell receptor repertoire,” Int J Mol Med, 4(3): 231-273 (1999).
[cited by applicant]
Waid et al., “A unique T cell subset described as CD4loCD40+ T cells (TCD40) in human type 1 diabetes,” Clinical Immunology, 124: 138-148 (2007).
[cited by applicant]
Waid et al., “Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells,” J Neuroimmunol, 270(1-2): 75-85 (2014).
[cited by applicant]
Waid et al., “Disruption of the homeostatic balance between autoaggressive (CD4+CD40+) and regulatory (CD4+CD25+FoxP3+) T cells promotes diabetes,” J Leukocyte Biol, 84: 431-439 (2008).
[cited by applicant]
Waid et al., “Peripheral CD4lo CD40+ auto-aggressive T cell expansion during insulin-dependent diabetes mellitus,” Eur J Immunol, 34: 1488-1497 (2004).
[cited by applicant]
Walling et al., “LFA-1 in T Cell Migration and Differentiation,” Frontiers in Immunology, 9: Article 952 (2018).
[cited by applicant]
Wang et al., “Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers,” Journal of Parenteral Science and Technology, 42(2S): S3-S25 (1988).
[cited by applicant]
Wikipedia, “Phosphate-buffered saline,” <https://en.wikipedia.org/wiki/Phosphate-buffered saline>: Accessed on Mar. 25, 2022 (Year: 2022).
[cited by applicant]
Winston et al., “Assessing Neuronal and Astrocyte Derived Exosomes From Individuals With Mild Traumatic Brain Injury for Markers of Neurodegeneration and Cytotoxic Activity,”
[cited by applicant]
Yu et al., “Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction,”
[cited by applicant]
Yu et al., “Targeting CD40 with a Selective Phage Display Derived Peptide,” Universiteit Leiden The Netherlands: 61-74 (2007).
[cited by applicant]
Zhang et al., “The regulation of integrin function by divalent cations,” Cell Adhesion & Migration, 6(1): 20-29 (2012).
[cited by applicant]
Extended European Search Report for Application No. EP 20840056.4, dated Jun. 14, 2023.
[cited by applicant]
Grant application entitled “Developing a small peptide to control autoimmune inflammation in type 1 diabetes” by PI: David H, Wagner and received on Sep. 2, 2016 and publicly available on Jan. 5, 2018, p. 1-46 (2018).
[cited by applicant]
Nelson et al., “Classification and etiology of diabetes in dogs and cats,” Thematic Review, T1-T9 (2014).
[cited by applicant]
Partial Supplementary European Search Report for EP Application No. EP 20840056.4 dated Mar. 23, 2023.
[cited by applicant]
Examination Report for EP Application No. 20840056.4 dated Oct. 21, 2024.
[cited by applicant]